Using health technology assessment across the spectrum of health care delivery—from services to biotechnologies—could curb some of the $1 trillion in spending on defects in value in the US.

Incorporating systems thinking into drug value assessment promises more realistic evaluations of the impact of new therapies, but it requires buy-in from policy makers, biopharmaceutical firms ...

Value assessment of new drugs and devices is gaining importance in the U.S. health care system. Pressure to do it right is accelerating.

To ensure that value assessment accounts for patient needs, we need a better understanding of the outcomes that are most important to patients, write authors from COVIA Health Solutions and the ...

Remember the buyer hierarchy The first step in assigning value to your customer list is to look at the big picture, keeping in mind the difference between customers and prospects. A house file will ...

Evidence-based assessments of the economic value of drugs can help control the escalating cost of drugs. So why doesn't the U.S. do this work and instead relies on other countries to do it?